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W E HAVE REPORTED in previous communications the isolation of a diabetogenic polypeptide from the urine of patients with lipoatrophic diabetes,l the urine of proteinuric diabetic patients without lipoatrophy,2 and the adenohypophysis of beef," sheep and pigs.4 The peptide from all these sources has been shown to induce hyperglycemia and resistance to exogenous insulin when administered to dogs or humans. Because the compound obtained from each of the above mentioned sources exhibits similar physicochemical and biological properties, it was concluded that the origin of the polypeptide found in the urine of diabetic patients is probably the pituitary gland. Since this conclusion was based on the isolation of a similar peptide from pituitary glands of cattle, sheep and pigs, w it became important to carry out parallel studies employing pituitary glands of man.
The purposes of the present paper are to outline a slightly modified procedure for the isolation and purification of the diabetogenic polypeptide from human pituitary glands, to demonstrate its antiinsulin and diabetogenic effects in dogs, and to compare its diabetogenic potency with that of human growth hormone and ovine prolacti,n.
MATERIALS AND METHODS
After a 2-yr period a sufficient number of human pituitary glands were collected from local hospitals to carry out these studies. After removal the glands were frozen. The active peptide was isolated according to the procedure outlined in Fig. 1 . Our previously published method for the extraction of bovine diabetogenic peptide is also suitable.3 Its isoelectric point (approximately pH 4.1) proved to be the same as that of the peptides obtained from animal adenohypophysis and from urine of proteinuric diabetic patients. The average yield is 0.03-0.04%. This material is designated as human PI.
The oxycellulose powder (16-22% COOH, Eastman Chemical Products, Inc., Kingsport. Tenn.) used in the procedure was kept refrigerated and before being used was washed successively with distilled water, 0.1 N HCl and distilled water. A Sephadex G-100 superfine descending column (0.9 X 60 cm) was used for the purification of human PI. The gel was equilibrated and eluted with 0.03 N HCI containing 0.2 M NaCl. Diabetogenic peptide (20 mg) was dissolved in 0.05 N HCl (0.6 ml) and applied to the column. The elution rate was 0.3 ml/20 min. The operating pressure was 20 cm. Protein was determined by the procedure of Lowry .6 The active polypeptide was recovered either by isoelectric point (pH 4.1) precipitation or by dialysis against distilled water. The procedure for acrylamide gel electrophoresis has been described previously.% Human growth hormone (lot 1-C) was obtained from the National Institute of Arthritis and Metabolic Diseases, National Pituitary Agency of the University of Maryland. This preparation has a biopotency of 1 I.U. per milligram. The hormone was dissolved in 2 ml of distilled water and administered subcutaneously as a single dose. Human growth hormone (Raben # 16) has a mean biopotency of 1.1 I.U. per milligram. The protein was dissolved in dilute hydrochloric acid and neutralized with 0.05 M NaOH to pH 7.0. Human growth hormone (Merck Sharp and Dohme C-1555) was dissolved in 2 ml distilled water and neutralized with 0.05 M NaOH to pH 7.0.
Ovine prolactin (NIH-P-S-7) was obtained from the National Institute of Health, Endocrinology Study Section, Bethesda, Md. This preparation has a mean Potency of 24.3 I.U. per milligram. The hormone was dissolved in 2 ml of distilled water and administered subcutaneously as a single dose.
Four trained normal dogs, two males and two females, were employed for biological assay. Maintenance and preparation of dogs for glucose and insulin tolerance tests have been previously described.4 The polypeptide was dissolved in 1.5 ml 0.05 N HCl and neutralized by dropwise addition of 0.05 N NaOH to pH 6.7-7.0. The solution was administered subcutaneously as a single dose. No untoward effects were observed. Blood glucose was determined by the Somogyi-Nelson procedure.6
Molecular weight estimation was carried out by the dodecyl sulfate-polyacrylamide gel electrophoresis procedure of Weber and Osborn. 7 Pure ovalbumin, chymotrypsinogen A, ribonuclease A and cytochrome C were used as protein standards.
RESULTS

The polypeptide
isolated from the human pituitary glands was tested for anti-insulin activity in two normal dogs (0 and T). Each animal was given a single subcutaneous injection of 1 mg of the polypeptide per kilogram of body weight. Insulin tolerance tests were carried out 10 and 34 hr after polypeptide administration. It is apparent (Fig. 2) that sensitivity to the hypoglycemic effect of exogenous insulin was significantly reduced. Insulin resistance was still evident in both animals 34 hr after polypeptide administration. The effect on glucose tolerance was studied in dogs P and L. Again a dose of 1 mg of polypeptide per kilogram of body weight was employed. Carbohydrate tolerance was greatly impaired in both animals (Figs. 3A and 4A) at 10 hr and less so at 34 hr. In dog L, 58 hr after polypeptide administration, glucose tolerance had returned to the preinjection level.
For comparative purposes, the same two animals (dogs P and L) were studied using bovine polypeptide. In dog P, two separate experiments with doses of 1 mg and 2 mg of bovine PI per kilogram of body weight were carried out with an interval of 13 days between them. The results are presented in Fig. 3B and 3C. One milligram per kilo of the human peptide appears to have induced the greatest decrease in glucose tolerance. In dog L, 2 mg/kilo of the bovine pcptide induced no change in glucose tolerance but the effect of 4 mg/kilo is seen in Fig. 4B . While the number of tests is too small to make a meaningful comparison, it appears that in both animals the human peptide induced the greater loss of glucose tolerance.
The effect of human growth hormone on glucose tolerance was also observed in dogs L and P. The dose was 0.125-1.0 mg of hormone per kilogram of body weight and glucose tolerance test was carried out 10 hr after each injection. The results are shown in Table 1 . It is clear that at these dose levels no significant change in glucose tolerance was observed in both of the animals. Ovine prolactin (0.5 mg/kilo) did not induce any significant change in glucose tolerance in dog P, the results are shown in Table 2 . In contrast, administration of 1 .O mg/ kilo of human PI in dog L induced a great decrease of glucose tolerance (Fig.  4A ). In dog P 0.5 mg/kilo of purified human PI induced significant intolerance to glucose. The results are shown in Table 3 . However, 0.25 mg/kg body weight of purified human PI did not provoke any significant alteration of glucose tolerance in this dog. F  '/2  1  1%  72  156  164  92  64  153  157  86  80  123  158  134   2  2%  3  59  68  66  58  70  76  76 69 69
* NIH-P-S-7. The effect of a highly purified polypeptide preparation (isoelectric point approximately pH 4.1) extracted from the urine of a proteinuric diabetic patient (C.S.) was studied on the same animal (dog L). One milligram per kilogram was administered subcutaneously as a single dose (Fig. 4C) . Its diabetogenic potency in this animal is clearly greater than that of the bovine peptide which was inactive at 2 mg/kilo. Figure 5 shows the Sephadex column chromatography profile of the diabetogenic polypeptide from human pituitary glands. The first peak has no diabetogenic effect in dogs. Disc acrylamide gel (7.5%, pH 8.8) electrophoresis of the active fraction is shown in Fig. 6 . The diabetogenic activity (0.5 mg/ kilo) of this fraction (second peak) is shown in Fig. 7 . Larger amounts are not available for testing.
Five separate molecular weight determinations of purified human PI by the method of Weber and Osborn give the following values: 20,500; 22,600; 19,600; 21,000 and 19,500. The molecular weight of the peptide as determined by this method appears to be approximately 20,600. A typical run is shown in Fig.  8 . 
DISCUSSION
A diabetogenic polypeptide has been isolated from human pituitary glands employing a slight modification of the procedure with which a similar polypeptide was previously isolated from adenohypophysis of cattle,3 sheep, and pigs.4 The physicochemical properties of the substance isolated from the adenohypophysis of all four species are similar to those of the peptides extracted from the urine of patients with lipoatrophic diabetes and from the urine of proteinuric diabetic patients without lipoatrophy.2 The isoelectric point of the active polypeptide isolated from all these sources is approximately pH 4.1. The possibility that the substance might be somatotropin is unlikely since the isoelectric point of human growth hormone is pH 4.9 and all material that precipitated at this pH was removed during our isolation procedure. Nevertheless, our polypeptide could still be contaminated with growth hormone since the disc acrylamide gel electrophoresis pattern indicates a small band before the large one. Antihuman growth hormone serum reacts with our substance to about 10% (performed by Dr. Ralph Knopf of our group) but the possibility that the cause of the glucose intolerance might be due to the presence of somatotropin in our preparation is remote since administration of 0.5-l .O mg/kilo 6 . Fig. 8 .-Molecular weight determination of human PI. Four marker proteins used were ovalbumin, 45,000; chymotrypsinogen A, 25,000; ribonuclease A, 13,700; and cytochrome C, 11,700. of human growth hormone does not provoke any significant change in carbohydrate tolerance in the same animals. Whether our human pituitary diabetogenie polypeptide (human PI) has any growth-promoting activity remains to be determined. It should be mentioned, however, that by means of the tibia test, our bovine pituitary diabetogenic polypeptide (bovine PI) exhibits no growth promoting activity.8 The chance that the peptide might be ACTH is also unlikely since the molecular weight of the two compounds are greatly different. We have shown previously that bovine PI3 and the diabetogenic polypeptide extracted from the urine of patients with lipoatrophic diabetes exhibit no adrenal stimulating activity in man .l The possibility that the peptide might be prolactin cannot be ruled out completely. In one experiment, ovine prolactin (0.5 mg/ kilo) did not induce any significant change in glucose tolerance in the same dog (dog P) in which human PI decreased it. By means of the Reece-Turner indermal pigeon crop technique, the diabetogenic polypeptide extracted from ovine adenohypophysis (ovine PI) has approximately 4 I.U. per milligram of prolactin activity.4 The molecular weight of human PI has now been determined to be 20,600; that of bovine PI is 26,OOO.lO
-
